|
KMID : 1011920150160010030
|
|
International Journal of Arrhythmia
2015 Volume.16 No. 1 p.30 ~ p.36
|
|
|
|
|
Uhm Jae-Sun
|
|
|
Abstract
|
|
|
|
It is well known that atrial fibrillation (AF) is the most important cause of cardioembolic stroke, while the left atrial appendage (LAA) is a common source of thrombus in patients with AF. The Watchman™ is an umbrella-shaped LAA occlusion device that can be implanted transvenously in the LAA via a delivery sheath for stroke prevention in patients with non-valvular AF. Warfarin can be discontinued 45 days after Watchman™ implantation. The PROTECT AF (Watchman™ Left Atrial Appendage System for Embolic Protection in Patients With AF) trial was the first prospective randomized trial to show that the Watchman™ was not inferior to warfarin for stroke prevention in patients with non-valvular AF. CAP (continuous access protocol) registry data, ASAP (ASA Plavix Feasibility Study With Watchman™ Left Atrial Appendage Closure Technology) registry data, and the PREVAIL (Watchman™ LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy)trial have confirmed this non-inferiority. The Watchman™ is expected as an alternative to oral anticoagulation therapy. Long-term data from the Watchman™ and from comparisons between the Watchman™ and new oral anticoagulants (NOACs) need to be evaluated. Great attention should be paid to the selection of patients for the Watchman™ implantation.
|
|
|
KEYWORD
|
|
|
atrial fibrillation, left atrial appendage, Watchman™
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
|
|